RO.CH

314

-2.12%↓

NOVN.CH

117.32

-1.56%↓

SDZ.CH

61.26

-1.89%↓

STMN.CH

77.04

-4.25%↓

BANB.CH

61.6

-0.96%↓

RO.CH

314

-2.12%↓

NOVN.CH

117.32

-1.56%↓

SDZ.CH

61.26

-1.89%↓

STMN.CH

77.04

-4.25%↓

BANB.CH

61.6

-0.96%↓

RO.CH

314

-2.12%↓

NOVN.CH

117.32

-1.56%↓

SDZ.CH

61.26

-1.89%↓

STMN.CH

77.04

-4.25%↓

BANB.CH

61.6

-0.96%↓

RO.CH

314

-2.12%↓

NOVN.CH

117.32

-1.56%↓

SDZ.CH

61.26

-1.89%↓

STMN.CH

77.04

-4.25%↓

BANB.CH

61.6

-0.96%↓

RO.CH

314

-2.12%↓

NOVN.CH

117.32

-1.56%↓

SDZ.CH

61.26

-1.89%↓

STMN.CH

77.04

-4.25%↓

BANB.CH

61.6

-0.96%↓

Search

Lonza Group AG

Fermé

SecteurSoins de santé

474.4 -1.7

Résumé

Variation du prix de l'action

24h

Actuel

Min

471

Max

482.9

Chiffres clés

By Trading Economics

Revenu

57M

483M

Ventes

-621M

3B

P/E

Moyenne du Secteur

37.129

57.833

Rendement du dividende

1.04

Marge bénéficiaire

16.345

Employés

19,771

EBITDA

-181M

822M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+41.85% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.04%

2.47%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.9B

34B

Ouverture précédente

476.1

Clôture précédente

474.4

Lonza Group AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 mars 2026, 17:44 UTC

Acquisitions, Fusions, Rachats

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

28 janv. 2026, 06:15 UTC

Résultats

Lonza Sales Grow on New Contract Momentum

23 juil. 2025, 08:30 UTC

Résultats
Principaux Mouvements du Marché

Lonza Shares Rise After Outlook Lift for Core Business

9 mars 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

6 mars 2026, 17:12 UTC

Acquisitions, Fusions, Rachats

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

6 mars 2026, 17:10 UTC

Acquisitions, Fusions, Rachats

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

6 mars 2026, 17:09 UTC

Acquisitions, Fusions, Rachats

Lonza to Retain 40% Stake in CHI

6 mars 2026, 17:08 UTC

Acquisitions, Fusions, Rachats

Lonza Will Receive Upfront Proceeds of CHF1.7B

6 mars 2026, 17:07 UTC

Acquisitions, Fusions, Rachats

Lonza: Transaction Expected to Close in 2H

6 mars 2026, 17:07 UTC

Acquisitions, Fusions, Rachats

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

6 mars 2026, 17:06 UTC

Acquisitions, Fusions, Rachats

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

28 janv. 2026, 12:04 UTC

Market Talk
Résultats

Lonza Results Show a Company in Good Shape -- Market Talk

28 janv. 2026, 05:35 UTC

Résultats

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

28 janv. 2026, 05:34 UTC

Résultats

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

28 janv. 2026, 05:33 UTC

Résultats

Lonza Issues 2026 View

28 janv. 2026, 05:32 UTC

Résultats

Lonza 2025 Core Ebitda Margin 31.6%

28 janv. 2026, 05:32 UTC

Résultats

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

28 janv. 2026, 05:32 UTC

Résultats

Lonza 2025 Core Ebitda CHF2.06B

28 janv. 2026, 05:30 UTC

Résultats

Analysts Saw Lonza 2025 Sales at CHF7.54B

28 janv. 2026, 05:30 UTC

Résultats

Lonza 2025 Sales CHF6.53B

27 oct. 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

23 oct. 2025, 10:53 UTC

Market Talk
Résultats

Lonza Set to Recover as Contracts Flow in -- Market Talk

23 juil. 2025, 08:00 UTC

Market Talk
Résultats

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 juil. 2025, 04:44 UTC

Résultats

Lonza 1H Sales Grew 19% at Constant Currency

23 juil. 2025, 04:43 UTC

Résultats

Lonza 1H Core Ebitda Margin 29.6%

23 juil. 2025, 04:43 UTC

Résultats

Lonza: Margins Will Be Only Minimally Affected

23 juil. 2025, 04:42 UTC

Résultats

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 juil. 2025, 04:42 UTC

Résultats

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 juil. 2025, 04:38 UTC

Résultats

Lonza 1H Net Pft CHF426M

23 juil. 2025, 04:37 UTC

Résultats

Lonza Backs 2025 View for CHI Business

Comparaison

Variation de prix

Lonza Group AG prévision

Objectif de Prix

By TipRanks

41.85% hausse

Prévisions sur 12 Mois

Moyen 683 CHF  41.85%

Haut 769 CHF

Bas 650 CHF

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

8

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
help-icon Live chat